Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old.
- People who have been newly diagnosed with multiple myeloma, confirmed using standard diagnostic guidelines.
- People whose disease is measurable through blood or urine tests showing certain protein levels above defined thresholds (confirm with trial site for specific values).
- People who are not suitable for high-dose chemotherapy with a stem cell transplant, due to being aged 65 or older, having a doctor's assessment of ineligibility, having a low physical functioning score, repeated failure to collect stem cells for transplant, or a personal decision to postpone transplant.
- People whose tumour cells test positive for two specific proteins called BCMA and GPRC5D.
- People whose liver and kidney function blood test results fall within acceptable ranges as defined by the trial (confirm with trial site for specific values).
- People who are able to understand and willing to sign a written consent form.
Who may not be able to join:
- People with an active condition called amyloidosis.
- People whose multiple myeloma has spread to the central nervous system (brain and spinal cord).
- People who have previously received a treatment targeting BCMA, or who have previously had CAR-T cell therapy.
- People with an active hepatitis B or hepatitis C infection.
- People with a known HIV infection.
- People whose life expectancy is estimated to be less than 6 months.
- People who are pregnant or breastfeeding.
- People with serious uncontrolled problems affecting the heart, lungs, brain, or other major organs.
- People who the principal investigator determines are not suitable for the trial for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-022-23909171
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sustained MRD-negative rate; Progression free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.